Daily US Times: The EU’s medicines regulator says there is no indication that the Oxford-AstraZeneca coronavirus vaccine is linked to an increased risk of blood clots.
The medicines regulator said the number of cases in vaccinated people was no higher than in the general population.
The statement came after a number of countries, including Norway and Denmark suspended the use of the Oxford-AstraZeneca Covid-19 vaccine.
The suspension followed reports that a small number of people had developed blood clots after receiving the jab.
There were also reports that a 50-year-old man had died in Italy after developing deep vein thrombosis (DVT) following a dose of Oxford-AstraZeneca Covid-19 vaccine.
On Thursday, the European Medicines Agency (EMA) said: “There is currently no indication that vaccination has caused these conditions, which are not listed as side effects with this vaccine.”
It added: “The vaccine’s benefits continue to outweigh its risks and the vaccine can continue to be administered while investigation of cases of thromboembolic events is ongoing.”
The EMA said there had been 30 cases of “thromboembolic events” among the five million Europeans who have received the vaccine.
AstraZeneca said the vaccine’s safety had been studied extensively in clinical trials. A spokesperson of the company said: “Regulators have clear and stringent efficacy and safety standards for the approval of any new medicine.”
In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) said there was no evidence the Oxford-AstraZeneca Covid-19 vaccine had caused problems, and people should still go and get vaccinated when asked to do so.
Phil Bryan of the MHRA said: “Blood clots can occur naturally and are not uncommon. More than 11 million doses of the Covid-19 AstraZeneca vaccine have now been administered across the UK.”